The purpose of this study was to perform dosimetry analyses comparing high-dose-rate brachytherapy (HDR-BT) with simulated stereotactic body radiotherapy (SBRT).
We selected six consecutive patients treated with HDR-BT monotherapy in 2010, and a CyberKnife SBRT plan was simulated for each patient using computed tomography images and the contouring set used in the HDR-BT plan for the actual treatment, but adding appropriate planning target volume (PTV) margins for SBRT. Then, dosimetric profiles for PTVs of the rectum, bladder and urethra were compared between the two modalities. The SBRT plan was more homogenous and provided lower dose concentration but better coverage for the PTV. The maximum doses in the rectum were higher in the HDR-BT plans. However, the HDR-BT plan provided a sharper dose fall-off around the PTV, resulting in a significant and considerable difference in volume sparing of the rectum with the appropriate PTV margins added for SBRT. While the rectum D5cm3 for HDR-BT and SBRT was 30.7 and 38.3 Gy (P < 0.01) and V40 was 16.3 and 20.8 cm3 (P < 0.01), respectively, SBRT was significantly superior in almost all dosimetric profiles for the bladder and urethra. These results suggest that SBRT as an alternative to HDR-BT in hypofractionated radiotherapy for prostate cancer might have an advantage for bladder and urethra dose sparing, but for the rectum only when proper PTV margins for SBRT are adopted.
Written by:
Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M, Konishi K, Yoshioka Y, Ogawa K. Are you the author?
Department of Radiation Oncology, NTT West Osaka Hospital, 2-6-40 Karasugatuji, Tennoji-ku, Osaka 543-8922, Japan; Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, Japan; Division of Medical Physics, Oncology Center, Osaka University Hospital, 2-15 Yamada-oka, Suita, Osaka, Japan; Department of Radiology, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nakasonecho, Kita-ku, Sakai, Osaka, Japan; Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Disease, 1-3-3 Nakamichi, Higashinari-ku, Osaka, Japan.
Reference: J Radiat Res. 2014 Jun 23. pii: rru048.
doi: 10.1093/jrr/rru048
PubMed Abstract
PMID: 24957754
UroToday.com Prostate Cancer Section
